FDA Orders Halt of Regulus’ Chronic Hepatitis C Trial

A second report of jaundice during Regulus Therapeutics’ trial evaluating RG-101 for the treatment of chronic hepatitis C virus infection has prompted the FDA to place a clinical hold on the study.

The company said it does not expect the hold to affect the timelines for three ongoing studies assessing the candidate.